Beam Therapeutics Inc. (BEAM) Investor Relations Documents

Beam Therapeutics Inc. (BEAM) investor relations documents from the company's IR site: 14 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-04	Press release	Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Coho
2026-07-23	Press release	Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in L
2026-06-18	Press release	Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylke
2026-05-18	Press release	Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
2026-05-13	Press release	Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
2026-05-12	Press release	Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability
2026-05-07	Press release	Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
2026-04-01	Press release	Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD
2026-03-25	Press release	Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Ant
2026-02-24	Press release	Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
2026-02-24	Press release	Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Di
2026-02-23	Press release	Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted
2026-01-11	Press release	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late
	Press release	Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020

BEAM overview · BEAM earnings · BEAM financials · BEAM KPIs · BEAM ownership · BEAM peers · BEAM filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.